Erasca, Inc.: Investors Invited to Join Proposed Securities Fraud Class Action

Erasca, Inc. Securities Fraud Lawsuit: Important Information for Investors

Erasca, Inc. (NASDAQ: ERAS) is currently facing a class action lawsuit due to allegations of securities fraud committed during the period between January 14, 2025, and April 26, 2026. The Rosen Law Firm, a globally recognized law firm specializing in investor rights, has issued reminders for those who purchased the company's common stock during this timeframe to consider participating in the legal action. The deadline to appoint a lead plaintiff is set for August 10, 2026.

The Significance of Joining the Class Action

Investors who acquired shares of Erasca, Inc. during the mentioned class period may be eligible for compensation without incurring upfront costs through a contingency fee arrangement. This lawsuit has already been initiated, and those interested in stepping up as lead plaintiff must take action before the deadline.

To participate fully, investors can visit the website Rosen Legal, or they can contact Phillip Kim, Esq., toll-free at 866-767-3653. Email inquiries can be directed to [email protected] for further assistance.

Allegations Against Erasca, Inc.

The claims against Erasca include violations of federal securities laws stemming from allegedly false and misleading statements made about their key oncology drug candidate, ERAS-0015. The lawsuit contends that throughout the class period, Erasca misrepresented the potential of ERAS-0015 as a